Public-Private Partnership in the Healthcare and Pharmaceutical Sectors of Kazakhstan: Problems and Solutions

  • Nurlyaiim T. ISSATAYEVA Department of Organization, Management and Economics of Pharmacy and Clinical Pharmacy, Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan
  • Ubaidilla M. DATKHAYEV Department of Organization, Management and Economics of Pharmacy and Clinical Pharmacy, Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan
  • Kairat S. ZHAKIPBEKOV Department of Organization, Management and Economics of Pharmacy and Clinical Pharmacy, Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan
  • Elmira A. SERIKBAYEVA Department of Organization, Management and Economics of Pharmacy and Clinical Pharmacy, Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan
  • Galiya Zh. UMIRZAKHOVA Department of Organization, Management of Pharmaceutical Affairs, Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan
DOI: https://doi.org/10.14505/jarle.v11.3(49).22

Abstract

Public-private partnership is one of the main ways to solve the social problems of modern states. In Kazakhstan, the main strategic direction of the development of the healthcare system is the modernization of existing medical organizations and the construction of new healthcare facilities. The purpose of the paper was to investigate the theory and practice of public-private partnership (PPP) in the healthcare and pharmaceutical sectors, to identify the main issues and find their solutions. The leading research method was the analysis and synthesis method, which enabled the characterization of attributes and principles of PPPs, allowed to classify, and consider the most striking examples. Considering the differences between PPP contracts, we addressed not only the functions and content of such contracts, but also the terms, and the risks involved. The advantages for each of the interested parties in PPP were analyzed: private sector, public sector, consumers. The analysis of the current state of PPPs in the field of interest in Kazakhstan was performed. The generalization of world experience and the analysis of best practices allowed to develop action-oriented proposals for the further development of PPPs in Kazakhstan’s healthcare, including those that concern attraction of foreign companies with regard to the issue of concessions in the field of medical and pharmaceutical infrastructure.

References

[1] Baimbetova, O. 2019a. Over the past 4 years, the volume of pharmaceutical production in Kazakhstan has doubled. Pharmaceutical Review of Kazakhstan. https://pharm.reviews/analitika/item/4341-za-poslednie-4-goda-ob-em-proizvodstva-farmproduktsii-v-rk-udvoilsya-s-37-do-79-mlrd-tenge.
[2] Baimbetova, O. 2019b. Pharmaceutical production in the EAEU in 2018. Express information. https://pharm.reviews/analitika/item/4387-proizvodstvo-farmatsevticheskoj-produktsii-v-eaes-v-2018-godu-ekspress-informatsiya.
[3] Birtanov, E.A. 2010. Organizational, Methodological and Financial and Economic Foundations of the Innovation and Investment Strategy for the Development of the Healthcare System of Kazakhstan. Almaty State Institute of Advanced Medical Studies of the Ministry of Health of Kazakhstan.
[4] Bondarenko, S. et al. 2018. Comparison of methods for determining the competitiveness of enterprises to determine market strategy. International Journal of Civil Engineering and Technology, 9(13): 890-898.
[5] Datkhayev, U. et al. 2016. Determination of seasonal demand for pharmaceutical staff. International Journal of Pharmaceutical Sciences Review and Research, 36(2): 105-111.
[6] Datkhayev, U.M. et al. 2019. Validation of spectrophotometric method for determination of thiamazole in liquids by dissolution test for the transdermal form. Pharmaceutical Chemistry Journal, 53: 572-576. DOI: 10.1007/s11094-019-02039-3.
[7] Kapitonov, I.A. 2019. International regulation of the restriction of the use of environment. Periodicals of Engineering and Natural Sciences, 7(4): 1681-1697.
[8] Karmaza, O.O. et al. 2018. Meditation in medicine: Comparative analysis of Ukrainian and foreign legislation. Journal of Legal, Ethical and Regulatory Issues, 21(Special Issue 1): 1-8.
[9] Margitich, V. 2002. Panorama of the global pharmaceutical market. https://www.apteka.ua/article/33193
[10] Naumenkova, S., Mishchenko, S. and Dorofeiev, D. 2019. Digital financial inclusion: Evidence from Ukraine. Investment Management and Financial Innovations, 16(3): 194-205.
[11] Naumenkova, S.V. 2015. Financial inclusivity: Economic contents and the approaches to its assessment. Actual Problems of Economics, 166(4): 363-371.
[12] Romanenko, Y.O. and Chaplay, I.V. 2016. Marketing communication system within public administration mechanisms. Actual Problems of Economics, 178(4): 69-78.
[13] Shertaeva, C. et al. 2014. Improvement of medicine provision of patients with a chronic obstructive lung illness on the basis of pharmaceutical and economical investigations. Life Science Journal, 11(9s): 16-23.
[14] Trusova, N. 2016. Systemic factors of projected financial potential of business entities. Economic Annals-XXI, 161(9-10): 61-65.
[15] Trusova, N.V. et al. 2018. Debt burden of the financial system of Ukraine and countries of the Eurozone: Policy of regulating of the risks. Espacios, 39(39): 1-10.
[16] Umurzakhova, G. et al. 2018. Communication skills as one of the main competences of pharmacists. Annals of Tropical Medicine and Public Health, 11: 62-69. DOI: 10.4103/ATMPH.ATMPH_194_17.
[17] Zhanaidarova, G.U. et al. 2019. Experimental research of harmine hydrochloride effect on internal organs. Bangladesh Journal of Medical Science, 18(3): 598-606.
*** An additional 6 PET centers will be opened in Kazakhstan. 2019. http://pharmnews.kz/ru/news/v-kazahstane-budut-otkryty-dopolnitelnye-6-pet-centrov_14958
*** Data of the Committee on Statistics of the Ministry of National Economy of Kazakhstan. 2020. https://economy.gov.kz/ru/kategorii/komitet-po-statistike.
*** Decree of the Government of Kazakhstan No. 395 ‘On approval of the Comprehensive Plan to Combat Cancer in Kazakhstan for 2018-2022’. 2018. https://tengrinews.kz/zakon/pravitelstvo_respubliki_kazahstan_premer_ministr_rk/zdravoohranenie/id-P1800000395/.
*** Health and pharmaceuticals. 2020. https://newsline.kz/ru/section/640/.
*** Investments in healthcare and social services decreased by 15% over the year. 2019. http://pharmnews.kz/ru/news/investicii-v-sferu-zdravoohraneniya-i-socialnyh-uslug-snizilis-na-15-za-god_15327.
*** New hospitals under PPP. 2019. http://pharmnews.kz/ru/news/novye-bolnicy-v-ramkah-gchp_15263.
*** Saparbayev instructed to reduce the terms of implementation of PPP projects in healthcare. 2019. http://pharmnews.kz/ru/news/saparbaev-poruchil-sokratit-sroki-realizacii-gchp-proektov-v-zdravoohranenii_15704.
Published
2020-06-15
How to Cite
ISSATAYEVA, Nurlyaiim T. et al. Public-Private Partnership in the Healthcare and Pharmaceutical Sectors of Kazakhstan: Problems and Solutions. Journal of Advanced Research in Law and Economics, [S.l.], v. 11, n. 3, p. 876 – 884, june 2020. ISSN 2068-696X. Available at: <https://journals.aserspublishing.eu/jarle/article/view/5172>. Date accessed: 22 dec. 2024. doi: https://doi.org/10.14505/jarle.v11.3(49).22.
Citation Formats
Issue
Vol 11 No 3 (2020): JARLE Volume XI Issue 3(49) Summer 2020
Section
Articles

The Copyright Transfer Form to ASERS Publishing (The Publisher)
This form refers to the manuscript, which an author(s) was accepted for publication and was signed by all the authors.
The undersigned Author(s) of the above-mentioned Paper here transfer any and all copyright-rights in and to The Paper to The Publisher. The Author(s) warrants that The Paper is based on their original work and that the undersigned has the power and authority to make and execute this assignment. It is the author's responsibility to obtain written permission to quote material that has been previously published in any form. The Publisher recognizes the retained rights noted below and grants to the above authors and employers for whom the work performed royalty-free permission to reuse their materials below. Authors may reuse all or portions of the above Paper in other works, excepting the publication of the paper in the same form. Authors may reproduce or authorize others to reproduce the above Paper for the Author's personal use or for internal company use, provided that the source and The Publisher copyright notice are mentioned, that the copies are not used in any way that implies The Publisher endorsement of a product or service of an employer, and that the copies are not offered for sale as such. Authors are permitted to grant third party requests for reprinting, republishing or other types of reuse. The Authors may make limited distribution of all or portions of the above Paper prior to publication if they inform The Publisher of the nature and extent of such limited distribution prior there to. Authors retain all proprietary rights in any process, procedure, or article of manufacture described in The Paper. This agreement becomes null and void if and only if the above paper is not accepted and published by The Publisher, or is with drawn by the author(s) before acceptance by the Publisher.